Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Site search
Search
Menu
Search
Subscribe
Home
Contact Us
Subscription Services
Promote Your Event
e-Edition
News
Sports
Entertainment
Obituaries
Photos
Videos
e-Edition
Classifieds
Place an Ad
Best of 2022
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Bristol Myers Squibb
< Previous
1
2
3
4
5
6
7
8
9
Next >
Bristol Myers Squibb and 2seventy bio Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma
November 20, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
TSVT
U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer (NSCLC)
November 15, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb to Participate in the 2023 Jefferies London Healthcare Conference
November 09, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
November 09, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb to Present Data from Innovative Cardiovascular Portfolio at the American Heart Association Scientific Sessions 2023
November 06, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb’s First Disclosures and New Data at ASH 2023 Highlight Company’s Leadership and Progress in Cell Therapy, Targeted Protein Degradation and Novel Approaches in Hematology
November 02, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb to Participate in the 2023 UBS BioPharma Conference
November 02, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Appoints Christopher Boerner, Ph.D., to Chair of the Board of Directors, Effective April 1, 2024
October 31, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Prices $4.5 Billion of Senior Unsecured Notes
October 30, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
October 30, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Reports Third Quarter Financial Results for 2023
October 26, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Announces U.S. FDA Breakthrough Therapy Designation for Investigational LPA1 Antagonist for Progressive Pulmonary Fibrosis
October 24, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Phase 3 CheckMate -67T Trial of Subcutaneous Nivolumab (nivolumab and hyaluronidase) Meets Co-Primary Endpoints in Advanced or Metastatic Clear Cell Renal Cell Carcinoma
October 19, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
The Robert A. Winn Diversity in Clinical Trials Award Announces Third Group of Physicians in Program to Increase Diversity in Clinical Trials
October 18, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Neoadjuvant Opdivo (nivolumab) with Chemotherapy Provides Benefits for Patients with Resectable Non-Small Cell Lung Cancer Across PD-L1 Expression Levels with Three-Year Follow Up in CheckMate -816 Trial
October 17, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy Followed by Opdivo Demonstrates Significant Survival Benefits for Cisplatin-Eligible Patients with Unresectable or Metastatic Urothelial Carcinoma in Phase 3 CheckMate -901 Trial
October 17, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo Shows Significant Improvement in Event-Free Survival for Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -77T Trial
October 17, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) as Adjuvant Treatment for Eligible Patients with Completely Resected Stage IIB or Stage IIC Melanoma1
October 13, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb to Showcase Data Demonstrating Improved Outcomes in Earlier Stages of Cancer, Durable Long-Term Benefits with Opdivo-Based Regimens, and Addressing High Unmet Needs in Multiple Tumor Types at ESMO 2023
October 12, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Sotyktu (deucravacitinib) Long-Term Data Demonstrate Durable Efficacy and Consistent Safety for up to Three Years in Moderate-to-Severe Plaque Psoriasis
October 11, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Presents New Zeposia (ozanimod) Data on Long-Term Disease Progression and Cognition in Patients with Relapsing Forms of Multiple Sclerosis
October 11, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati Therapeutics
October 08, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
MRTX
Bristol Myers Squibb to Report Results for Third Quarter 2023 on October 26, 2023
September 26, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Announces Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer
September 22, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Announces Dividend
September 20, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Highlights Advancing Pipeline and Differentiated Research Platforms to Support Long-Term Sustainable Growth at R&D Day
September 14, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Six-Year Outcomes from Phase 3 CheckMate -227 Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) in the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer
September 11, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb’s Investigational LPA1 Antagonist Reduces Rate of Lung Function Decline in Progressive Pulmonary Fibrosis Cohort of Phase 2 Study
September 09, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Celebrates a Decade of Its Coast 2 Coast 4 Cancer Cross-Country Bike Ride in Support of the V Foundation for Cancer Research
September 07, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
September 01, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.